Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications

British Journal of Haematology

Volumn 93, Issue 1, 1996, Pages 81-88

  Garcia Sanz R ^a   Gonzalez M ^a   Orfao, A ^a   Moro, Ma J ^a   Hernandez J M ^a   Borrego, D ^a   Carnero, M ^a   Casanova, F ^a   Barez A ^a   Jimenez R ^a   Portero, J A ^a   San Miguel, J F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

biology; flow cytometry; multiple myeloma; NK cells; NK associated antigens

Indexed keywords

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD56; ANTIGENS, CD57; BONE MARROW; FEMALE; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECEPTORS, IGG;

EID: 9244243598     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.4651006.x     Document Type: Article

References (53)

1. Bergsagel, P.L., Kuehl, W.M., Belch, A.R. & Pilaski, L.M. (1994) CDR3 analysis identities circulating clonal B-lymphocytes in multiple myeloma. International Conference: Multiple Myeloma, from Biology to Therapy: Current Concepts, Mulhouse, France, October 1994, p. 65.
2. Bianchi, A., Dodd, L. & Kornbluth, J. (1990) Selective deficiency in the ability of LAK cells from patients with multiple myeloma to lyse myeloma tumor cells. (Abstract). Blood, 76, (Suppl.), 201.
3. Bladé, J., San Miguel, J.F., Alcalá, A., Maldonado, J., Sanz, M.A., García-Conde, J., Moro, M.J., Alonso, C., Besalduch, J., Zubizarreta, A., Besses, C., González Brito, G., Hernández-Martín, J., Fernández-Calvo, J., Rubio, D., Ortega, F., Jiménez, R., Colominas, P., Faura, M.V., Font, L., Tortosa, J., Domingo, A., Fontanillas, M., Rozman, C. & Estapé. C (1993) Alternating combination VCMP/ VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. Journal of Clinical Oncology, 11, 1165-1171.
4. Börset, M., Johnsen, A.C., Hjerner, Ö. & Waage, A. (1994) Myeloma cell lines produce the NK-cell-activating cytokines IL-7, IL-12 and TNF. International Conference: Multiple Myeloma, from Biology to Therapy: Current Concepts, Mulhouse, France, October 1994, p. 34.
5. Chronic Leukemia-Myeloma Task Force. National Cancer Institute (1973) Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Reports, 4, 145-158.
6. Cimino, G., Avvisati, G., Amadori, S., Cava, M.C., Giannarelli, D., Di Nucci, G.D., Magliocca, V., Petrucci, M.T., Poti, G., Sgadari, C. & Mandelli, F. (1990) High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. British Journal of Haematology, 73, 373-377.
7. Durie, B.G.M. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer, 36, 842-854.
8. Epstein, J. (1992) Myeloma phenotype: clues to disease origin and manifestation. Hematology/Oncology Clinics of North America, 6, 249-256.
9. Erkeller-Yuksel, F.M., Deneys, V., Yuksel, B., Hannet, I., Hulstaert, F., Hammilton, C., Mackinnon, H., Turner Stokes, L., Munhyeshuli, V., Vanlangendarck, P., De Bruyére, M., Bach, B.A. & Lydyard, P.M. (1992) Age-related changes in human blood lymphocyte subpopulations. Journal of Pediatrics, 2, 216-222.
10. Facon, T., Bleder, A., Labalette-Houache, M., Jouet, J.P., Bauters, F. & Dessaint, J.P. (1993) Simultaneous evaluation on natural killer (NK) associated antigens and NK activity in multiple myeloma (MM): a report on 45 patients. (Abstract). XIIth Meeting of the International Society of Haematology, Vienna, Austria, 1993, p. 672.
11. Gherman, M., Manciulea, M., Bancu, A.C., Sulica, A., Stanworth, D.R. & Herberman, R.B. (1987) Regulation of human natural cytotoxicity by IgG-I: characterization of the structural site on monomeric IgG responsible for inhibiting natural killer cell activity. Molecular Immunology, 24, 743-750.
12. González, M., San Miguel, J.F., Gascón, A., Moro, M.J., Hernández, J.M., Ortega, F., Jiménez, R., Guerras, L., Romero, M., Casanova, F., Sanz, M.A., Portera, J.A. & Orfäo, A. (1992) Increassed expression of natural killer-associated and activated antigens in multiple myeloma. American Journal of Hematology, 39, 84-89.
13. Haller, O., Hansson, M., Kiessling, R. & Wigzell, H. (1977) Role of non-conventional natural killer cells in resistance against syngenic tumour cells in vivo. Nature, 270, 609-611.
14. Harada, H., Kawano, M.M., Huang, N., Harada, Y., Iwato, K., Tanabe, O., Tanaka, H., Sakai, A., Asaoku, H. & Kuramoto, A. (1993) Phenotypic difference of normal plasma cell from mature myeloma cells. Blood, 81, 2658-2663.
15. Herberman, R.B. & Ortaldo, J.R. (1981) Natural killer cells: their role in defense against disease. Science, 214, 24-30.
16. Hogan, P.G. & Basten, A. (1988) What are natural killer cells and what do they do? Blood Reviews, 2, 50-58.
17. Hoover, R.G. & Kornbluth, J. (1992) Immunoregulation of murine and human multiple myeloma. Haematology Oncology Clinics of North America, 6, 407-424.
18. + monoclonal B lineage cells in peripheral blood of myeloma patients as late-stage B cells. Blood, 78, 711-719.
19. Jondal, M. (1987) The human NK cell: a short overview and a hypothesis on NK recognition. Clinical and Experimental Immunology, 70, 255-262.
20. Kiessling, R., Hansson, M. & Gronberg, A. (1984) Natural killer cells as regulators of malignant and normal cell growth. Progress in Immunology: V (ed. by Y. Yamamura and T. Tada). pp. 1181-1198. Academic Press, Tokyo.
21. Kimata, H., Shanahan, F., Brogan, M., Targan, S. & Saxon, A. (1987) Modulation of ongoing human immunoglobulin synthesis by natural killer cells. Cell Immunology, 107, 74-88.
22. Komiyama, K., Crago, S.S., Itoh, K., Moro, I. & Mestecky, J. (1986b) Inhibition of natural killer cell activity by IgA. Cell Immunology, 101, 143-155.
23. Lanier, L.L. & Jackson, A.L. (1992) Monoclonal antibodies: differentiation antigens expressed on leukocytes. Manual of Clinical Laboratory Immunology. Section D: Immune Cell Phenotyping by Flow Cytometry (ed. by N. R. Rose et al), pp. 157-163. American Society for Microbiology, Washington, D.C.
24. Lanier, L.L., Phillips, J.H., Hackett, J., Tutt, M. & Kuman, V. (1986) Natural killer cells: definition of a cell type rather than a function. Journal of Immunology, 137, 2735-2739.
25. Lucivero, G., D'Addario, V., Tannoia, N., Dell'Osso, A., Gambatesa, V., Lopalco, P.L. & Cagnazzo, G. (1991) Ontogeny of human lymphocytes: two-color fluorescence analysis of circulating lymphocyte subsets in fetuses in the second trimester of pregnancy. Fetal Diagnosis and Therapy, 6, 101-106.
26. Mandelli, F., Avissati, G., Amadori, S., Boccadoro, M., Gernone, A., Lauta, V.M., Marmont, F., Petrucci, M.T., Tribalto, M., Vegna, M.L., Dammacco, F. & Pileri, A. (1990) Maintenance treatment with alpha-2b recombinant interferon significantly improves response and survival duration in multiple myeloma patients responding to conventional induction chemotherapy: results of an Italian randomized study. New England Journal of Medicine, 322, 1430-1434.
27. McDaniel, H.L., MacPherson, B.R., Tindle, B.H. & Lunde, J.H. (1992) Lymphoproliferative disorder of granular lymphocytes: a heterogeneous disease. Archives of Pathology and Laboratory Medicine, 116, 235-238.
28. Nagler, A., Lanier, L.L., Cwirla, S. & Phillips, J.H. (1989) Comparative studies of human FcR III-positive and negative natural killer cells. Journal of Immunology, 143, 3183-3191.
29. + NK cells. Journal of Immunology, 148, 2429-2436.
30. Nielsen, H., Nielsen, H.J., Tvede, N., Klarlund, K., Mansa, B., Moesgaard, F. & Drivsholm, A. (1991) Immune dysfunction in multiple myeloma: reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors. APMIS, 99, 340-346.
31. Norusis, M.J. (1990) SPSS Base System User's Guide. SPSS 4.0 for the Macintosh. SPSS Inc., Chicago.
32. Ogata, S., Maimonis, P.J. & Itzkowitz, S.H. (1992) Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Research, 52, 1741-1746.
33. Ogmundsdottir, H.M. (1988) Natural killer cell activity in patients with multiple myeloma. Cancer Detection and Prevention, 12, 133-143.
34. Orfào, A., García-Sanz, R., López-Berges, M.C., Vidriales, M.B., González, M., Caballero, M.D. & San Miguel, J.F. (1994) A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry, 17, 332-339.
35. Ortaldo, J.R. & Herbermann, R.B. (1984) Heterogeneity of natural killer cells. Annual Review of Immunology, 2, 359-394.
36. Österborg, A., Nilsson, B., Björkholm, M., Holm, G. & Mellstedt, H. (1990) Natural killer cell activity in monoclonal gammopathies: relation to disease activity. European Journal of Haematology, 45, 153-157.
37. Pilarski, L.M. & Jensen, G.S. (1992) Monoclonal circulating B cells in multiple myeloma. Hematology/Oncology Clinics of North America, 6, 297-322.
38. Rees, R. C. (1990) MHC restricted and non-restricted killer lymphocytes. Blood Reviews, 4, 204-210.
39. Reichert, T., DeBruyere, M., Deneys, V., Tötterman, T., Lydyard, P., Yuksel, F., Chapel, H., Jewell, D., Van Hove, L., Linden, J. & Buchner, L. (1991) Lymphocyte subset reference ranges in adult caucasians. Clinical Immunology and Immunopathology, 60, 190-208.
40. Richards, S.J. & Scott, C.S. (1992) Human NK cell in health and disease: clinical, functional, phenotypic and DNA genotypic characteristics. Leukemia and Lymphoma, 7, 377-399.
41. Robertson, M.J. & Ritz, J. (1990) Biology and clinical relevance of human natural killer cells. Blood, 76, 2421-2438.
42. San Miguel, J.F., Gárcia-Sanz, R. González, M., Moro, M.J., Hernández, J.M., Ortega, F., Borrego, D., Carnero, M., Casanova, F., Jiménez, R., Portero, J.A. & Orfào A. (1995) A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood, 85, 448-455.
43. San Miguel, J.F., González, M., Gascón, A. Moro, M.J., Hernández, J.F., Ortega, F., Jiménez, R., Guerras, L., Romero, M., Casanova, F., Sanz, M.A., Sánchez, J., Portero, J.A. & Orfào, A. (1991) Lymphoid subsets and prognostic factors in multiple myeloma. British Journal of Haematology, 80, 305-309.
44. San Miguel, J.F., Ojeda, H., González, M., Orfào, A., Caǹizo, M.C., Sánchez, I. & López-Borrasca, A. (1989) Prognostic value of immunological markers in acute leukemia. Leukemia, 3, 108-111.
45. Sansoni, P., Cossarizza, A., Brianti, V., Fagnoni, F., Snelli, G., Monti, D., Marcato, A., Passeri, G., Ortolani, C., Forti, E., Fagiolo, U., Passeri, M. & Franceschi, C. (1993) Lymphocyte subsets an natural killer cell activity in healthy old people and centenarians. Blood, 82, 2767-2773.
46. Shimazaki, C., Alzpodien, J., Wisniewsky, D., Gulati, S.S., Kolitz, J.E., Fried, J. & Clarkson, B.D. (1988) Cell-mediated toxicity of interleukin-2 activated lymphocytes against autologous and allogeneic human myeloma cells. Acta Haematologica, 80, 203-209.
47. Takahashi, T., Makiguchi, Y., Hinoda, Y., Kakiuchi, H., Nakagawa, N., Imai, K. & Yachi, A. (1994) Expression of MUC1 on myeloma cells and induction of HLA-inrestricted CTL against MUC1 from a multiple myeloma patient. Journal of Immunology, 153, 2102-2109.
48. Timonen, T., Ortaldo, J. & Herberman, R.B. (1981) Characteristics of human large granular lymphocytes and relathioship to natural killer and T cells. Journal of Experimental Medicine, 153, 569-582.
49. Trinchieri, G. (1989) Biology of natural killer cells. Advances in Immunology, 47, 187-376.
50. Uchida, A., Yagita, M., Sugiyama, H., Hoshino, T. & Moore, M. (1984) Stong NK cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. International Journal of Cancer, 34, 375-381.
51. Van Camp, B., Durie, B.G.M., Spier, C., De Waele, M., Van Riet, I., Vela, E., Frutiger, V. & Richter, L. (1990) Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1: Leu-19). Blood, 76, 377-382.
52. Vidriales, M.B., Orfào, A., López-Berges, M.C., González, M., Hernández, J.M., Ciudad, J., López, A., Moro, M.J., Martinez, M. & San Miguel, J.F. (1993) Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution. Annals of Hematology, 10, 217-222.
53. Westin, J., Cortelezzi, A., Hjorth, M., Rodgers, J., Turesson, I. & Zador, G. (1990) Interferon-alpha-2b therapy during the plateau phase of multiple myeloma. V Hannover Interferon Workshop, IFN Therapy in B Cell Malignancies, Hannover, Germany, p. 50.